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Abstract
Complex I deficiency, either specific or associated with other respiratory chain defects, has been identified in
myopathies, encephalomyopathies and in three ‘neurodegenerative’ disorders: Parkinson’s disease, dystonia and Leber’s
hereditary optic neuropathy. The complex I defect is expressed in blood in all these three but, to date, only in LHON have
specific mitochondrial DNA mutations been identified. Recent work with r8 cybrids indicates that, in a subgroup of patients
at least, the complex I deficiency is determined by mtDNA, in contrast to dystonia where a nuclear gene defect or toxic
influence appears a more likely cause. The actions of specific toxins, e.g., MPTP continue to play an important role in our
understanding of pathogenesis of neurodegeneration, particularly in PD. q 1998 Elsevier Science B.V.
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1. Introduction
 .NADH ubiquinone reductase complex I is the
first enzyme protein complex of the mitochondrial
respiratory chain. Details of the structure and func-
tion of complex I will be described elsewhere in this
issue, and this review will focus on neurodegenera-
tive disorders associated with complex I deficiency.
Complex I comprises 41 subunits of which seven
 .ND1, ND2, ND3, ND4, ND4L, ND5 and ND6 are
 .encoded by mitochondrial DNA mtDNA . Numerous
mutations of mtDNA have now been associated with
w xhuman disease 1 . In the majority of cases, mutations
result in a demonstrable defect of respiratory chain
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activity. Multiple respiratory chain deficiencies, e.g.,
decreased activity of complex I and complex IV, are
seen more frequently than isolated defects. This is
because the majority of mtDNA mutations involve
 .transfer RNAs tRNA , abnormal functioning of
which will inevitably affect those polypeptides with
the relevant constituent amino acid. However, three
neurodegenerative diseases are associated with iso-
lated or predominant complex I deficiency: Parkin-
 .son’s disease PD , focal dystonia and Leber’s heredi-
 .tary optic neuropathy LHON .
2. Parkinson’s disease
PD is characterised clinically by bradykinesia,
rigidity and tremor. Onset is usually in the sixth or
seventh decades of life and lifetime risk is estimated
at 1 in 40. Pathologically, there is severe degenera-
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tion and cell loss in the substantia nigra pars com-
pacta, predominantly if not exclusively affecting
dopaminergic neurones and their projections to the
striatum. Other areas of the central nervous system
are affected including the locus ceruleus
 .noradrenergic and substantia innominata
 .cholinergic . Ubiquitin-rich intracycloplasmic
 .eosinophilic inclusions Lewy bodies are seen in a
proportion of surviving neurones. Symptomatic treat-
ment is based on dopamine receptor activation by
 .dopamine replenishment via L-dopa or dopamine
receptor agonists. However, the disease is progressive
and no intervention has been shown unequivocally to
alter progression.
The aetiology and pathogenesis of PD are un-
known but recent discoveries have provided evidence
that both the environment and hereditary may play
some role. 1-Methyl-4-phenyl 1,2,3,6 tetrahydropyri-
 .dine MPTP was produced as a synthetic meperidine
analogue for use as a ‘designer’ narcotic, but found
to be capable of inducing parkinsonism within 7–14
w xdays of injection 2 . MPTP appears to induce clinical
features similar to, but not identical with, idiopathic
PD, but which still remain responsive to dopamine
receptor activation. Pathological study of a brain
from an MPTP addict with parkinsonism showed
severe destruction of dopaminergic neurones in the
w x 18substantia nigra 3 . -Fluorodopa positron emission
tomography in patients with MPTP parkinsonism in-
dicated progression of nigrostriatal cell loss over 7
years at a rate faster than aging and comparable with
w xidiopathic PD 4 . This implies that the toxicity of
this compound continues long after initial exposure
and indicates the presence of ongoing biochemical
abnormalities causing cell death.
MPTP is systemically distributed following intra-
venous injection but targets the dopaminergic neu-
rones of the substantia nigra through specific uptake
 w x .and conversion mechanisms see Ref. 5 for review .
MPTP is a protoxin, metabolised to its active deriva-
 q.tive 1-methyl-4-phenylpyridinium MPP by
 .monoamine oxidase B MAO-B , the distribution of
which therefore determines the site of toxicity. MAO-
B concentration is highest in the glial cells of the
CNS, thereby defining this area as highest in MPPq
concentration. MPPq is a substrate for the dopamin-
ergic re-uptake pathway and so results in high con-
centration in nigrostriatal dopaminergic neurones.
MPPq is then accumulated by mitochondria via an
energy dependent system for cations. MPPq is a
specific reversible inhibitor of complex I and results
in a fall in ATP levels. MPPq probably interacts with
complex I at the same site as rotenone and piericidin
w x qA 6 . MPP induces more severe and irreversible
inhibition of complex I if cytochrome oxidase com-
. w xplex IV is inhibited 7 . This inhibition was pre-
vented with free radical scavengers indicating oxida-
tive damage of complex I under these conditions.
Complex I inhibition results in increased free radical
generation from the respiratory chain and so the
MPPq model suggests that a self amplifying cycle of
complex I deficiency and damage may result in pro-
gressive cell damage. Such a situation would fit well
with the progressive striatal lesion in MPPq exposed
patients as determined by 18-fluorodopa PET.
MPTP parkinsonism can be induced in monkeys
w xand other vertebrates 8 , although some species, e.g.,
rats are relatively resistant. In addition, older mon-
keys and rats seem more sensitive to the effects of
w x qMPTP 9,10 . There is increasing evidence that MPP
generates free radicals and oxidative damage in addi-
w xtion to causing complex I inhibition 11,12 . For
instance, the nitric oxide synthase inhibitor 7-
w xnitroindazole has been shown to protect monkeys 13
w xand rats 14 . However, there is also evidence that
7-nitroindazole inhibits MAO-B, and this would pre-
q w xvent conversion of MPTP to MPP 15 . Other fac-
tors may also influence the effects of MPTP and in
this respect it is interesting that only a very small
proportion of addicts exposed to MPTP actually de-
veloped parkinsonism. This raises the possibility that
genetic influences may play some role in determining
susceptibility.
Complex I deficiency in PD brain was first de-
w xscribed in 1989 16 and provided a direct biochemi-
cal link between MPTP parkinsonism and the idio-
pathic disease. Numerous studies have followed to
understand the cause of the complex I defect and its
relation, if any, to the aetiology and pathogenesis of
PD. Early work focused on the anatomic and disease
specificity of the mitochondrial abnormality see Ref.
w x .17 for review . Using post mortem brain ho-
mogenates, no deficiency was identified in cortex,
cerebellum, caudate, putamen, tegmentum, globus
pallidus or, subsequently, cingulate cortex or substan-
w xtia innominata 18 . Interestingly, an identical distri-
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bution was found for a significant reduction in re-
w xduced glutathione 18,19 . The substantia innominata
is predominantly cholinergic but is also involved in
 .degeneration in PD see Section 1 . The findings of
complex I activity and GSH concentrations suggest
that they do not contribute to either cholinergic cell
death or Lewy body formation in this area. The latter
proposition is also supported by normal complex I
function and GSH levels in the cingulate cortex of
 .patients with ‘dementia with Lewy bodies’ DLB —
an area with a particularly high concentration of
Lewy bodies. Thus it would seem that mitochondrial
dysfunction and oxidative stress are linked both to
each other and to the PD substantia nigra within the
brain.
Almost all the PD brains studied biochemically
have come from patients treated with L-dopa during
life. It was therefore important to establish whether
this drug could affect complex I activity. In vitro
studies, and in vivo studies in rats, indicated that
L-dopa could induce a 20–25% reversible inhibition
w xof complex I 20 . Dopamine concentrations are high
 .in the striatum caudate, putamen in PD patients and
these sites would therefore be expected to demon-
strate any drug-related complex I deficiency. How-
ever, mitochondrial function in these areas is normal
w x21,22 .
 .Patients with multiple system atrophy MSA have
severe dopaminergic cell death in the substantia nigra
and present with core clinical features similar to
idiopathic PD. MSA patients are given L-dopa for
symptomatic relief in doses similar to, or greater
than, PD patients. Analyses of mitochondrial function
in substantia nigra and other brain areas in MSA have
w xnot identified any defect 22,23 . These observations
also address the question as to whether the complex I
deficiency in PD is simply a result of neuronal
degeneration. The absence of any defect in MSA, in
the presence of severe neuronal loss, indicates that
the complex I abnormality is not simply a reflection
of cell death. This is also supported by the observa-
tions in other neurodegenerative diseases where anal-
yses of mitochondrial function in brain have demon-
strated different defects e.g., complex IIrIII defi-
 .ciency in Huntington’s disease HD caudate nucleus
w x24 and complex IV deficiency in Alzheimer’s dis-
 . w xease AD brain 25 . Thus isolated complex I defi-
ciency is not a product of neural death.
Studies on the tissue expression of the mitochon-
drial defect in muscle and platelets in PD produced
w xconflicting results. Both in vivo spectroscopic 26,27
 w xand in vitro biochemical analysis see 17 for re-
.view suggested either no defect or multiple defects.
However, the majority of patients in these studies
showed no mitochondrial abnormality. The reasons
for the discrepancies are not clear but may lie in
patient sampling, different experimental methods and,
perhaps most importantly, different aetiological fac-
tors.
In contrast, almost all studies on platelet mitochon-
drial function in PD have demonstrated a defect of
 w x.complex I function see Refs. 17,28 . The severity
of the deficiency did vary between studies, with most
showing a ;25% reduction, whilst some showed
defects up to 50%. On plotting PD patients against
matched controls, however, it was clear that there
was overlap between control and PD complex I activ-
ity, and the assay was too insensitive to use as a
w x‘diagnostic test’ 29 . Nevertheless, the presence of a
mitochondrial defect in a site distant from the sub-
stantia nigra has important implications for our un-
derstanding of the cause of this abnormality. Platelets
 .do have some pharmacological they contain MAO-B
 q.and uptake they concentrate MPP mechanisms
w xwhich are similar to dopaminergic neurones 30 and
these could render platelets and dopaminergic neu-
rones susceptible to the same or similar toxins which
may cause the mitochondrial defect in both. Candi-
date toxins have included the isoquinolines and the
 .b-carbolines. 1,2,3,4-Tetrahydroisoquinoline TIQ
and 2-methyl-TIQ are both structurally related to
MPTP and both have been found in human brain,
including a patient with PD in whom the level of TIQ
w xwas greater than controls 31,32 . TIQ can be toxic to
dopaminergic neurones and induce motor deficits in
monkeys. Interestingly, TIQ is also a complex I
w xinhibitor 33 . N-methyl TIQ is a methylation product
of TIQ and is a substrate for MAO-B, producing
 q. qn-methyl-isoquinolinium NMIQ . NMIQ inhibits
tyrosine hydroxylase and MAO. It is found in certain
foodstuffs and can cross the blood brain barrier, but
can also be formed by condensation reaction in the
brain. b-carbolines are also structurally related to
MPTP and can also be formed in the brain by
condensation reaction. They are only poorly concen-
trated in mitochondria and induce inhibition of com-
( )A.H.V. SchapirarBiochimica et Biophysica Acta 1364 1998 261–270264
w xplexes I–III 34 . b-carbolines are not readily taken
up into dopaminergic neurones and are weak nigral
toxins even after intrastriatal infusion.
A n a lte rn a tiv e e x p la n a tio n to a n
environmentalrtoxic cause for the complex I defect
in both substantia nigra and platelets is that both are
caused by a genetically determined abnormality. As
both nuclear and mitochondrial genomes contribute
 .to complex I polypeptides, the mutation s could be
in either one. A method recently described, using
 0.mtDNA-less r cells as a recipient for donor
mtDNA, offers an opportunity to dissect out the
w xcause of the platelet complex I deficiency in PD 35 .
r0 cells are derived from a cell line following expo-
sure to ethidium bromide over several passages. The
r0 cells have mitochondria but no mtDNA and no
functioning respiratory chain and they require a
medium enriched in pyruvate and uridine to survive
and grow. Platelets are derived from megakaryocytes
in the bone marrow and so their mitochondrial pro-
teins are derived from the host nucleus and mitochon-
drial genomes in the normal fashion. Platelets them-
selves are budded off from the megakaryocyte and so
enter the circulation with mitochondria but no nu-
cleus. Thus they represent an ideal unit for fusion
with r0 cells. Platelets act as donors of mtDNA to the
resulting fusion cybrid, whilst the r0 cell provides the
nuclear environment. Subsequent growth and cloning
of the fusion cybrid produces daughter cells derived
from the r0 nuclear background but with the donor
mtDNA. Using this system, it can be predicted that,
if the complex I deficiency present in PD platelet
mitochondria is retained in fusion cybrids after growth
and passage, the complex I defect must be the result
of a mutation or mutations in PD platelet mtDNA.
This is because the only remnant of the PD platelets
in the daughter fusion cybrids is the mtDNA. Con-
versely, if the complex I defect is lost then the cause
must be either in PD nuclear DNA or due to a
circulating toxin.
A putative mtDNA defect is unlikely to be the
cause of all PD and so we have suggested that those
patients with the lower platelet complex I activity
might be those most likely to carry such a mutation
w x29 . A mtDNA mutation might be expected to result
in observable maternal inheritance of a disease. Whilst
occasional families with maternally inherited PD do
w xexist 36 , the majority occur as sporadic cases or in
w xautosomal dominant families 37 . However, the ma-
jority of patients with mtDNA mutations associated
with disease have no family history, including 40%
of LHON patients with the 11778 mutation see
.below . Thus, the lack of maternal inheritance in PD
does not exclude a role for mtDNA, at least in a
proportion of cases.
We selected eight patients with complex I activity
)1 S.D. below control mean and showed that this
w xdefect was consistent over time 38 . Platelets from
these patients were then individually fused with
A549r0 cells. Interestingly, the fusion cybrids grew
more slowly than the matched control cybrids. Analy-
sis of the PD fusions provided evidence for a mtDNA
defect underlying the complex I defect in these pa-
tients.
 .1 The PD fusion clones had a specific 25%
decrease in citrate synthase corrected complex I ac-
 .tivity ps0.007 . There was a significant correlation
between an individual control or PD patient’s com-
plex I activity and their cybrid complex I activity.
 .This implies that the donor mtDNA control or PD
was a major factor determining complex I function.
Furthermore, correlation of platelet and cybrid com-
plex I enabled a more clear and sensitive distinction
between PD and controls.
 .2 MtDNA mutations are invariably heteroplasmic
and are randomly distributed to daughter cells during
cloning. We hypothesised that if the PD cybrids
carried a heteroplasmic mtDNA mutation, cloning
would produce cells with variable respiratory chain
activity, depending upon the mutant load in each
clone. This hypothesis was proved correct.
 .a Cloning of one of the PD patients produced a
series of clones with a range of respiratory chain
activity. Eight of 16 PD clones had complex Ircitrate
synthase ratios )1 S.D. below the control mean, and
ten of 16 clones had complex IV activities )1 S.D.
below control mean. Overall, there was a mean 25%
reduction in complex I and 20% decrease in complex
IV.
 .  .b Cytochrome oxidase COX, complex IV histo-
chemistry in clonal cells with the 3243 ‘MELAS’
mutation demonstrated significant intercellular vari-
ability. Some cells stained strongly, whilst others
stained weakly or not at all. This is thought to be a
reflection of the variation in the 3243 mutant load
between cells, which if 095% results in complex IV
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deficiency in A549r0 cells. Similar staining of the
PD clones produced an identical pattern, some cells
staining normally whilst others were COX negative.
Control clonal cells all stained positively for COX.
 .c Double fluorescent staining with Mitotracker—
a mitochondrial stain—and a monoclonal antibody to
the mtDNA encoded COI subunit of COX showed
that all PD clones had mitochondria and, whilst some
had normal COX I binding, other cells had none or
very little. The loss of COI staining in these cells
implied defective mtDNA COI translation. This was
also a pattern identical to that seen in 3243 ‘MELAS’
clones. Control clonal cells all stained with both
Mitotracker and COI.
 .d Finally, using JC-1, a fluoroprobe sensitive to
 .mitochondrial membrane DC potential and an in-m
direct measure of respiratory chain activity, produced
a heterogeneous intercellular pattern in the PD clones
 .indicating some had normal DC but others hadm
 .low DC implying low respiratory chain function.m
Again, all control clones produced a normal and
 .uniform DC staining pattern.m
These results produce strong but as yet indirect
evidence for a mtDNA mutation in PD platelets and
are in agreement with a previous study of PD mixed
w xcybrids 39 . Direct sequencing of small numbers of
unselected PD patients has been undertaken but with-
w xout positive results 40–43 . We would suggest that
informative mtDNA sequences are more likely to be
derived from PD patients selected for their low com-
plex I activity, as these patients probably constitute
the subgroup most likely to carry relevant mtDNA
mutations.
A putative mtDNA mutation capable of producing
a platelet mitochondrial complex I defect would be
the most likely cause of the complex I deficiency in
PD substantia nigra. MtDNA mutations are usually
systemically distributed, although the proportion of
mutation load will vary from one tissue to another.
To some extent this may explain the variable results
seen in skeletal muscle in PD patients, some with,
and others without, a mtDNA defect. Even in those
who do have a mtDNA mutation, a variable mutation
load may result in a defect in some but not others. If
a mtDNA defect results in a complex I defect in
substantia nigra, it is likely that other factors in the
nigra will exacerbate such a defect. There is clear
evidence of oxidative stress and damage in the PD
 w x .substantia nigra see Ref. 44 for review . Already
outlined above is the reciprocal relationship between
a respiratory chain defect and free radical generation.
In addition, auto-oxidation of neuromelanin and the
w xpresence of increased, possibly ‘free’ iron 45,46
will further enhance the toxic environment for com-
plex I. Furthermore, the use of L-dopa may, as dis-
cussed above, exacerbate the complex I deficiency.
Thus, it is our proposition that any inborn complex I
defect in PD is enhanced by the biochemistry and
pharmacology of the substantia nigra.
If a mtDNA mutation is present in a proportion of
PD patients, how does it induce dopaminergic cell
death? Firstly, neurones are particularly dependent on
oxidative phosphorylation as an energy source—thus
a defect in the respiratory chain may have a dispro-
portionate effect on survival. Secondly, as outlined
above, other factors may exacerbate the mitochon-
drial deficiency in the nigra. Thirdly, the proportion
of mtDNA mutations may vary according to anatomi-
cal location and only those above a specific threshold
may suffer sufficient nigral neuronal death to induce
PD. Given these factors, the most likely direct result
of the mtDNA mutation and complex I deficiency
will be a fall in ATP levels. The results of ho-
mogenate studies indicate that there is a 30–40%
complex I defect in PD substantia nigra, such an
abnormality being likely to involve both neurones
and glia but more severely affecting neurones. The
simplest explanation is therefore that the dopaminer-
gic neurones die from a fall in ATP levels. However
it is unlikely that this is the only cause, oxidative
damage, calcium release and probably additional as
yet unknown factors also contributing.
Cells may die by necrosis or apoptosis. Apoptosis
is characterised by certain morphological features
including chromatin condensation and the formation
of apoptotic bodies but with the retention of or-
ganeller structure. A number of factors have been
shown to induce apoptotic cell death including free
w x w x q w x w xradicals 47 , L-dopa 48 , MPP 49 and TIQ 50 .
Recent evidence suggests that MPPq, rotenone and
TIQq induce apoptosis via a free radical related
w xmechanism 50 . Thus the biochemical defects al-
ready identified in PD substantia nigra, or compounds
known to induce complex I deficiency and parkinson-
ism, are also know to cause apoptosis. There is some
evidence that apoptotic cell death may also occur in
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w xPD 51 although others have found no apoptotic
w xchanges 52 . Apoptosis occurs rapidly and so may be
 .missed when a single time point time of death is
selected for study. Furthermore, apoptotic cell death
may occur more frequently in the early stage of PD
w xthan in late end stage disease 49 . Against these
factors must be balanced the possibility that agonal
state may itself increase the proportion of cells under-
going apoptosis. Nevertheless, the presence of so
many proapoptotic factors in PD makes this mode of
cell death a possible, if not probable, contributor to
pathology. If so, this would allow the development of
novel forms of neuroprotection.
Recent research has highlighted the important role
that mitochondria play in apoptosis. r0 cells, despite
the lack of a respiratory chain, still generate sufficient
 . w x 0 qenergy to maintain DC 53 . Both r and rm
 .  .normal cells lose their DC and generate freem
radicals in response to agents that stimulate apopto-
sis. These events precede nuclear DNA fragmentation
in both r0 and rq cells, although they take place at a
0  .slower rate in r cells. The loss of DC is them
result of the opening of permeability transition pores,
w xor mega-channels 54 . Permeability transition and
 .DC collapse result in the release of moleculesm
10–15 kDa in size capable of inducing chromatin
w xcondensation in isolated nuclei 55 , one of which is
w xcytochrome c 56 . These events appear to be impor-
tant early steps in apoptosis. A mtDNA mutation and
complex I defect will adversely affect ATP synthesis
 .and cause a fall in DC —as shown in the PDm
cybrids with JC-1 staining. Although such a fall in
 .DC may be insufficient to result in apoptosis, itm
may ‘prime’ cells such that additional biochemical
insults, e.g., free radicals, may cause sufficient col-
 .lapse of DC to induce apoptotic cell death. If thism
is shown to be of relevance to PD, new neuroprotec-
tive agents directed to maintaining mitochondrial
 .DC could be developed and tested.m
In summary, there is now compelling evidence for
a complex I defect in PD and that in a proportion of
cases at least, this deficiency is caused by a mtDNA
abnormality. Further research is now being directed
to identifying the relevant mtDNA sequence changes.
Once these are defined, their relationship with the
complex I deficiency can be investigated along with
any interaction such mutation may have with envi-
ronmental agents. The mitochondrial contribution to
PD pathogenesis has also stimulated the search for
new agents that might retard or prevent neuronal loss.
3. Dystonia
 .Idiopathic torsion dystonia ITD is the commonest
form of primary dystonia. Autosomal dominant genes
with reduced penetrance and variable expression
probably account for the majority of patients with
w xsegmented, multifocal and generalised ITD 57,58 .
The DYT1 gene responsible for early onset gener-
alised dystonia has been mapped to 9q34 and recently
w xshown to encode an ATP binding protein 59 . The
pathology of dystonia is thought to involve the basal
ganglia, although the biochemical abnormalities that
may cause dystonia are not understood. Interestingly,
dystonia is seen relatively commonly in patients with
w xmitochondrial myopathy 60 including Leigh’s syn-
w xdrome 61 , Furthermore several families with
LHON-dystonia and specific mtDNA mutations have
 .been described see below .
In 1992, one study reported a specific defect of
complex I activity in platelet mitochondria from pa-
tients with segmental, generalised and focal dystonia
w x62 . This group found that complex I function was
reduced by 62% in segmental and generalised dysto-
nia patients, and by 37% in those with focal dystonia,
providing some parallel in mitochondrial dysfunction
with the severity and extent of the dystonia. How-
ever, a subsequent report found no abnormality of
respiratory chain activity in patients with focal or
w xgeneralised dystonia 63 . This area was further inves-
tigated by studying patients with generalised dystonia
whose linkage to DYT1 was defined, and in patients
w xwith sporadic, focal dystonia 64 . Results showed a
significant decrease in mean citrate synthase cor-
rected platelet complex I activity 22% decrease,
.ps0.001 in patients with focal dystonia. However,
there was no abnormality in mitochondrial function
found in patients with generalised dystonia, whether
or not they were linked to DYT1. This study there-
fore confirmed the previous observation of a specific
complex I deficiency in focal dystonia. The lack of
any association of DYT1 with a complex I defect
suggests that the nuclear mutation in this disorder
does not involve mitochondrial dysfunction.
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The association of a platelet complex I deficiency
with focal dystonia raises similar questions with re-
gard to aetiology and pathogenesis as were discussed
in the section on PD. The presence of this abnormal-
ity in a site distant from pathology naturally raises
the prospect of a genetically determined biochemical
defect with variable expression and pathological con-
sequences. As in PD, the complex I defect in the
patients with focal dystonia may be encoded by a
nuclear or mitochondrial gene. In order to address
this issue, the r0 cybrid system was applied to
platelets from patients with focal dystonia. In contrast
to the PD patients, the dystonia mtDNA transformed
A549r0 cells did not perpetuate the complex I defi-
ciency on subsequent passage. This was further ex-
amined by undertaking clonal analysis and, again in
contrast to the PD patients, there was no significant
variation in either complex I or complex IV in the
w xdaughter clones 65 . Cell histochemistry, COI im-
munohistochemistry and JC-1 staining all showed
homogeneous intercellular patterns, again contrasting
with that seen in PD.
These studies in A549-dystonia cybrids have im-
portant implications.
 .1 The cybrid analysis in both mixed culture and
clonal lines from focal dystonia patients suggests that
the cause of the complex I defect is not related to
mtDNA but rather to a nuclear defect or circulating
toxin.
 .2 The ‘negative’ results obtained with the dysto-
nia patients who demonstrated a platelet complex I
.defect of similar severity to PD patients , using the
same A549 nuclear background as in the PD fusion
studies. serves to emphasise the importance and va-
lidity of the data implicating mtDNA as the cause of
the complex I defect in the PD patients studies.
Further progress in studying the relationship of the
complex I defect in dystonia is limited by accessibil-
ity to brain samples—it is not known whether any
mitochondrial defect occurs in basal ganglia or other
areas of the dystonia brain.
4. Leber’s hereditary optic neuropathy
LHON is the commonest cause of blindness in
otherwise healthy young men with an incidence of
approximately 1 in 50 000. Presentation is usually
with subacute painless sequential visual loss usually
.within 8 weeks with early fundoscopic changes of a
peripapillary telangiectatic microangiopathy, with
subsequent development of optic atrophy. Recovery
of vision is variable and may be related to the
underlying mutation. The frequency of the presence
of additional neurological features is difficult to de-
w xtermine but a multiple sclerosis-like illness 66 , cere-
w x w xbella ataxia 67 , peripheral neuropathy 68 and dys-
 .tonia see below have all been described in LHON
families. whilst one study suggested additional neuro-
w xlogical abnormalities in 27 of 46 LHON patients 69 ,
only 7 of 107 LHON patients were found to be
w xsimilarly affected 70 .
Maternal inheritance in LHON was recognised
w xearly 71 and made this disorder an ideal subject for
mtDNA analysis. Several mtDNA mutations have
w xnow been identified in LHON: G11778A 72 ,
w x w xG3460A 73 and T14484C 74 in the ND4, ND1
and ND6 complex I genes respectively. These three
mutations are considered ‘primary’ in that no addi-
tional mtDNA mutations are required to cause the
disease and they are not seen in controls. Sixteen
other mutations have also been associated with
LHON; these are termed ‘secondary’ mutations be-
cause either the mutations must occur together in
some combination or because their pathogenicity is in
doubt as they are found in controls and result in base
w xchanges of doubtful significance 75 .
The G11778A mutation in ND4 is found in excess
of 50% of all LHON families whilst the other two
w xprimary mutations are found in 10–20% 76 . In the
G11778A families, there is 95% penetrance of LHON
by age 50 years. The primary mutations are virtually
homoplasmic or heteroplasmic with high mutant load
in the blood of LHON families. There is little rela-
tionship between mutant load and the risk of develop-
ing LHON, and both symptomatic and asymptomatic
family members may carry identical mutant loads.
This, together with the observation that there is a
preponderance of affected males 4.3:1 for the
.G11778A mutation has lead to the suggestion that
additional factors, nuclear or environmental, may be
involved in determining LHON. The presence of a
visual loss susceptibility locus on the X chromosome
might explain some of these observations. However,
linkage analysis over 169cM of the X chromosome
w xhas excluded involvement 77 . Lyonisation favouring
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an X-linked susceptibility locus could also explain
the pedigree patterns in LHON, but investigation has
w xfailed to identify any skewed inactivation 78 .
Functional defects of complex I have been re-
ported in all three primary mutations. Decreased
 .NADH CoQ reductase activity by ;65% has1
been described in platelets from patients with the
w xG3460A mutation 79–81 and the T14484C muta-
w xtion 82 . Impaired oxygen consumption with com-
plex I linked substrates has been observed in the
w xG11778 mutation 80,83 . These respiratory chain
defects appear widespread and have been seen in
lymphocytes and skeletal muscle, as well as platelets.
Interestingly, although a significant complex I defect
was demonstrated polarographically in the G11778A
w xmutation 80 . Only a mild enzymatic deficiency was
present—and then observed only when corrected for
w xsmoking habit 81 . We have recently shown that the
severe enzymatic defect in the G3460A mutation is
not associated with a decrease in ATP synthesis.
Thus there seems to be little relationship between the
presence of the G3460A mutation and its effect on
energy metabolism. This, coupled with the lack of
discriminatory effect of the presence of the primary
mutations in inducing LHON amongst siblings high-
lights the need for clearer insight into the patho-
genicity of these mutations.
We proposed that the nuclear background of a cell
might influence the biochemical expression of a pri-
mary LHON mutation. This might help explain the
 .apparent tissue specificity to the optic nerve in a
high proportion of patients. The G3460A mutation
was chosen for this analysis as it had a clear bio-
chemical marker in terms of its severe enzymatic
complex I defect. When platelets homoplasmic for
 . 0this mutation were fused with 143B bone derived r
cells, and expanded by clonal analysis, there was a
mean ;60% decrease in complex I enzyme activity
—paralleling that observed in the parent platelets
w x84 . When similar experiments using fusion and
clonal analysis were undertaken using an A549 lung
.derived nuclear background, however, there was no
significant difference in mean complex I activities.
These results demonstrate that the nuclear environ-
ment can influence the expression of the complex I
defect in LHON patients with the A3460G mutation.
Previous reports have identified several families
with LHON-dystonia. A ;80% defect in complex I
activity was identified in platelets from a family with
LHON and CNS disease including dystonia, who
carried the T14484C mutation together with a further
w xmutation at base pair 4160 in ND1 85,86 . A second
family was found to have a mutation in ND6 at base
w xpair 14459 87 , with defective complex I activity
which persisted following transfer to a r0 cell line
w x88 . A third family with LHON-dystonia and a muta-
tion at 11696 in ND4, in association with a ‘sec-
ondary mutation’ at 14596 in ND6, has been de-
w xscribed 89 . Biochemical analysis of skeletal muscle
from a patient of this last family showed a 79%
decline in complex I function associated with less
severe decreases in the activities of complex II–IV.
All the LHON-dystonia families exhibited maternal
inheritance. The results from these families are of
particular interest, bearing in mind the finding of
complex I deficiency in focal dystonia.
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